ClinicalTrials.gg
CompletedNCT05350098Updated Oct 16, 2026

Efficacy of Plant-protein Diets in Patients With Chronic Kidney Disease

An interventional study of Plant-protein Diets and Control Diets in Chronic Kidney Disease Stage 5, sponsored by Osaka University. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Osaka University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 16, 2026Now CompletedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 102 studies in Renal Insufficiency, Chronic with a site in Japan — 13 open to participants now, 21 under way, 12 of them phase 3. Renal Insufficiency, Chronic · Japan.

Enrollment
75th of 88
40 · median 216
Started
2023
with 5 others
No phase
2 of 102
none open now
Registered
73rd of 102
by date

Among the 102 studies in Renal Insufficiency, Chronic with a site in Japan, this one is the 75th largest by enrollment of the 88 interventional ones that give a count, is one of 6 that started in 2023, is one of 2 with no phase, and was the 73rd registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

13 of the 102 studies in Renal Insufficiency, Chronic with a site in Japan are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Renal Insufficiency, Chronic with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of plant-protein diets for 12 weeks in patients with advanced chronic kidney disease.

03

Conditions studied

  • Chronic Kidney Disease Stage 5

Keywords

  • plant-protein diets
  • chronic kidney disease
  • uremic solutes
  • metabolic acidosis
  • chronic kidney disease-mineral and bone disorder
  • gut microbiome
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. patients with chronic kidney disease who were referred to the Outpatient Department of Nephrology at Osaka University Hospital
  2. \< 20 mL/min/1.73 m2
  3. taking anigiotensin-converting enzyme inhibitors or angiotensin Ⅱ receptor blockers or angiotensin receptor neprilysin inhibitor
  4. K \< 5.5 mEq/L

Exclusion criteria

Exclusion Criteria:

  1. Being planned to intitate renal replacement therapies within 3 months
  2. Having inflammatory bowel diseases
  3. History of gastrointestinal tract surgery
  4. Taking antibiotics within 1 month before the entry
  5. Taking or being planned to start warfarin
  6. Having dietary allergies
  7. Having difficulty in oral intake
  8. During pregnancy or breastfeeding
  9. Unsuitable for participant in the trial by an attending physician
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    A dietary intervention of plant-protein based diets

    Other: Plant-protein Diets

  • Active comparator
    A dietary intervention of control diets

    Other: Control Diets

Interventions

  • OtherPlant-protein Diets

    Participants will consume meals with 70% plant-based protein three times a day. Participants will be prohibited to have meals other than experimental diets and to drink milk and soy milk.

  • OtherControl Diets

    Participants will consume meals with 50% plant-based protein three times a day. Participants will be prohibited to have meals other than experimental diets and to drink milk and soy milk.

06

What researchers measure

Primary outcomes

  1. Change in serum levels of indoxyl sulfate, p-Cresyl sulfate and trimethylamine N-Oxide

    Time frame: 4 weeks after starting intervention

Secondary outcomes

  1. Change in eGFR

    Time frame: 4 weeks after starting intervention

  2. Change in urinary protein creatinine ratio

    Time frame: 4 weeks after starting intervention

  3. Change in serum bicarbonete levels

    Time frame: 4 weeks after starting intervention

  4. Change in urinary citrate to creatinine ratio

    The measurement of this outcome was abandoned because of the end of sales for its measuring reagent (F-kit citrate; JK International, Tokyo, Japan) in Japan on December 23, 2022. This decision had been made before we initiatited the recruitement of study participants.

    Time frame: 4 weeks after starting intervention

  5. Change in blood pressure

    Time frame: 4 weeks after starting intervention

  6. Change in serum levels of calcium, phosphate, intact parathyroid hormone and intact fibroblast growth factor 23

    Time frame: 4 weeks after starting intervention

  7. Change in serum levels of acetic acid, propionic acid and butyric acid

    Time frame: 4 weeks after starting intervention

  8. Diversity and composition of the gut microbiota

    Time frame: 4 weeks after starting intervention

  9. Change in muscle mass

    Time frame: 4 weeks after starting intervention

  10. Dietary adherence

    How many times participants have the study diet during the study period.

    Time frame: 4 weeks after starting intervention

  11. The number of oral medications including antihypertensive drugs, diuretics, potassium tablets, potassium binders, phosphate binders, calcium tablets, active vitamin D3 analogs and sodium bicarbonate

    Time frame: 4 weeks after starting intervention

07

Study locations

1 site
  • Department of Nephrology, Osaka University
    Suita, Osaka 5650871, Japan
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Mar 2024, 14 months.

Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's 14 months is below that.

Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2022
First posted
Apr 27, 2022
StartActual
Jan 1, 2023
Primary completionActual
Mar 30, 2024
CompletionActual
Mar 30, 2024
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Active, not recruiting→Completed
    + 3 other changes: index terms, verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05350098
Lead sponsor
Osaka University
Responsible party
Yusuke Sakaguchi (assistant professor, Osaka University) — Principal investigator
First posted
Apr 27, 2022
Start date
Jan 1, 2023
Primary completion
Mar 30, 2024
Completion
Mar 30, 2024
Last update
Oct 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion